×
0 0 -0.000378357926598487 -0.00548618993567914 0.00472947408248203 0.0147559591373439 -0.00908059023836543 -0.00643208475217549
Stockreport

Ultragenyx says three patients in phase 1/2 gene therapy study had positive results [MarketWatch]

ULTRAGENYX PHARMACEUTICALS INC (RARE)  More Company Research Source: MarketWatch
Last ultragenyx pharmaceuticals inc earnings: 8/2 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.ultragenyx.com/investor-relations
PDF Ultragenyx says three patients in phase 1/2 gene therapy study had positive results Ultragenyx Pharmaceutical Inc. RARE, -0.71% shares rose 2.5% in premarket trade Wednesday after the company said that the first dose cohort of three patients in a phase 1/2 gene therapy study had "positive longer-term safety and efficacy" results. Moreover, after 24 weeks, the first patient dosed decided to discontinue all alternate medication three weeks ago and "continues to do well," Ultragenyx Chief Executive Emil Kakkis said. While the first patient's urea formation rate was increased "substantially" over 24 weeks, the second and third patients did not show a clinically meaningful change in rate of urea formation over 20 weeks and 12 weeks, Ultragenyx said. The gene therapy, DTX301, is being developed for ornithine transcarbamylase deficiency, a genetic disorder that can cause acute and chronic neurological deficits and other toxicities; an estimated 10,000 patients have OTC deficiency worldwid [Read more]

IMPACT SNAPSHOT EVENT TIME: RARE
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
RARE alerts

from News Quantified
Opt-in for
RARE alerts

from News Quantified